The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. The metric has seen a significant loss of -15.39% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 163.67%. Over the past 30 days, the price of ALGS has fallen by 22.31%. And in the last five days, it has fallen by -15.34%.
Aligos Therapeutics Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $46.80 on 01/06/25, while the lowest price for the same period was registered at $6.76 on 10/08/24.
52-week price history of ALGS Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Aligos Therapeutics Inc’s current trading price is -27.97% away from its 52-week high, while its distance from the 52-week low is 398.67%. The stock’s price range during this time has been between $6.76 and $46.80. The trading volume for the Healthcare sector company’s shares reached about 0.67 million for the day, which was higher than the average daily volume of 0.42 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Aligos Therapeutics Inc (ALGS) has experienced a quarterly rise of 334.41% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 120.95M and boasts a workforce of 66 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 18.49, with a change in price of +20.58. Similarly, Aligos Therapeutics Inc recorded 307,027 in trading volume during the last 100 days, posting a change of +156.79%.
ALGS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ALGS stands at 0.18. Similarly, the long-term debt-to-equity ratio is also 0.11.
ALGS Stock Stochastic Average
Today’s raw stochastic average for Aligos Therapeutics Inc over the last 50 days is 65.88%.This indicates a increase from the raw stochastic average of the past 20 days, which was 30.37%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 48.33% and 61.79%, respectively.
